Malaria – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Malaria Market Outlook
Thelansis’s “Malaria Market Outlook,
Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034"
covers disease overview, epidemiology, drug utilization, prescription share
analysis, competitive landscape, clinical practice, regulatory landscape,
patient share, market uptake, market forecast, and key market insights under
the potential Malaria treatment modalities options for eight major markets
(USA, Germany, France, Italy, Spain, UK, Japan, and China).
Malaria Overview
Malaria is
an acute febrile illness that arises from the transmission of Plasmodium
parasites through the bites of infected female Anopheles mosquitoes. In humans,
five parasite species are capable of causing malaria, with P. falciparum and P.
vivax posing the most significant risk. P. falciparum is Africa’s most
prevalent and deadliest parasite species, while P. vivax dominates in most
countries outside of sub-Saharan Africa. The onset of malaria symptoms, which
include fever, headache, and chills, usually occurs 10-15 days after the
infective mosquito bite. These symptoms can be mild and difficult to recognize
as malaria. However, if left untreated, P. falciparum malaria can quickly
progress to severe illness and death within 24 hours. Fever is a hallmark
symptom of malaria that is triggered by the release of parasites every 2 to 3
days, depending on the Plasmodium species. High parasite burdens can result in
severe and life-threatening malaria, causing hemolysis and severe anemia, or
end-organ damage due to vascular adherence of infected erythrocytes and micro
occlusion.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment